Advertisement

Rheumatology International

, Volume 38, Issue 4, pp 631–640 | Cite as

Patient and physician perspectives on the impact of health-related quality of life in Mexican patients with ANCA-associated vasculitis

  • Andrea Hinojosa-Azaola
  • Ariadna Jiménez-González
  • Natasha Alcocer-CastillejosEmail author
Observational Research

Abstract

The objective of this study is to describe aspects of health-related quality of life (HRQOL) in Mexican patients with antineutrophil cytoplasmic-associated vasculitis (AAV). Cross-sectional comparison study includes patients with established AAV and a comparison group with rheumatoid arthritis (RA), chronic kidney disease (CKD), and healthy subjects. Variables considered were: socio-demographic data, comorbidities, laboratory, disease activity, damage, and Physician’s and Patient’s Global Assessment (PhGA and PtGA). The following measurements were done: Pittsburg sleep quality index, Multidimesional Fatigue Inventory (MFI-20), Hospital Anxiety and Depression Scale, Short Form 36 questionnaire (SF-36), and Health Assessment Questionnaire. 60 patients with AAV were included, median age 54 years, and 60% female. Significant differences were found only in the bodily pain domain of the SF-36 (p = 0.01). Aspects of disease relevant for AAV patients were: fatigue and lack of energy; visual abnormalities; neuropathy; renal impairment; arthritis, and sinusitis. Greater total score on MFI-20 (p < 0.001) and worse PtGA (p = 0.01) were associated with worse physical health. Higher PhGA values were associated with worse physical quality of life (p = 0.01). Greater fatigue score (p = 0.002), greater anxiety-depression score (p = 0.005), and worse PtGA (p = 0.01) were associated with worse mental health quality of life. No differences were found in prevalence of sleep impairment, anxiety, depression, or disability between groups. AAV patients experienced more general and physical fatigue (p < 0.0001), and reduced activity (p = 0.01) than healthy subjects, but similar to RA and CKD patients. Vasculitis has negative effects on patients’ physical and mental HRQOL.

Keywords

ANCA Vasculitis Quality of life Patient-reported outcomes 

Notes

Acknowledgements

The authors would like to thank Irazú Contreras Yáñez for her valuable help in the scoring and interpretation of the SF-36 and HAQ-DI scales.

Author contributions

AHA and NAC designed the study; AHA, AJG, and NAC participated in acquisition of data; AHA, AJG, and NAC analyzed and interpreted data; AHA and NAC drafted the manuscript; AHA, AJG, and NAC revised the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Funding

None.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Supplementary material

296_2017_3904_MOESM1_ESM.docx (145 kb)
Online 1. STROBE Statement. Online Resource 2. AAV patients with and without sleep disorder. Online Resource 3. AAV patients with and without depression or anxiety (DOCX 145 KB)

References

  1. 1.
    Walsh M, Mukhtyar C, Mahr A et al (2011) Health related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Care Res (Hoboken) 63:1055–1061CrossRefGoogle Scholar
  2. 2.
    Basu N, Jones GT, Fluck N et al (2010) Fatigue: a principal contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology 49:1383–1390CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Merkel PA, Aydin SZ, Boers M et al (2014) Current status of outcome measure development in vasculitis. J Rheumatol 41:593–598CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Herlyn K, Hellmich B, Seo P, Merkel PA (2010) Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res (Hoboken) 62:1639–1645CrossRefGoogle Scholar
  5. 5.
    Merkel PA, Aydin SZ, Boers M et al (2011) The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 38:1480–1486CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    McClean A, Morgan MD, Basu N et al (2016) Physical fatigue, fitness, and muscle function in patients with antineutrophil cytoplasmic antibody–associated vasculitis. Arthritis Care Res (Hoboken) 68:1332–1339CrossRefGoogle Scholar
  7. 7.
    Brezinova P, Englbrecht M, Lovric S et al (2013) Coping strategies and depressiveness in primary systemic vasculitis—what is their impact on health-related quality of life? Rheumatology 52:1856–1864CrossRefPubMedGoogle Scholar
  8. 8.
    Carpenter DM, Thorpe CT, Lewis M et al (2009) Health-related quality of life for patients with vasculitis and their spouses. Arthritis Care Res (Hoboken) 61:259–265CrossRefGoogle Scholar
  9. 9.
    Carpenter DM, Meador AE, Elstad EA et al (2012) The impact of vasculitis on patients’ social participation and friendships. Clin Exp Rheumatol 30:S15-S21PubMedCentralGoogle Scholar
  10. 10.
    Tomasson G, Boers M, Walsh M et al (2012) Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res (Hoboken) 64:273–279CrossRefGoogle Scholar
  11. 11.
    Trieste L, Palla I, Baldini C et al (2012) Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 30:S154-S156Google Scholar
  12. 12.
    Instituto Nacional de Estadística y Geografía (INEGI) (2017) Estadísticas a propósito del Día Mundial de la Justicia Social, Boletín Informativo. http://www.inegi.org.mx. Accessed 17 Feb 2017
  13. 13.
    Flossmann O (2015) Risks of treatments and long-term outcomes of systemic ANCA-associated vasculitis. Presse Med 44:e251–e257CrossRefPubMedGoogle Scholar
  14. 14.
    Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11CrossRefPubMedGoogle Scholar
  15. 15.
    Leavitt RY, Fauci AS, Bloch DA et al (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener’s granulomatosis. Arthritis Rheum 33:1101–1107CrossRefPubMedGoogle Scholar
  16. 16.
    Aletaha D, Neogi T, Silman AJ et al (2010) 2010 Rheumatoid Arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRefPubMedGoogle Scholar
  17. 17.
    Levin A, Stevens PE (2014) Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 85:49–61CrossRefPubMedGoogle Scholar
  18. 18.
    Basu N, McClean A, Harper L et al (2014) The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis 73:207–211CrossRefPubMedGoogle Scholar
  19. 19.
    Stone JH, Hoffman GS, Merkel PA et al (2001) A disease specific activity index for Wegener’s granulomatosis: Modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 44:912–920CrossRefPubMedGoogle Scholar
  20. 20.
    Exley AR, Bacon PA, Luqmani RA et al (1997) Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides. Arthritis Rheum 40:371–380CrossRefPubMedGoogle Scholar
  21. 21.
    Buysse DJ, Reynolds CF, Monk TH et al (1989) The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193–213CrossRefPubMedGoogle Scholar
  22. 22.
    Mollayeva T, Thurairajah P, Burton K et al (2016) The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: a systematic review and meta-analysis. Sleep Med Rev 25:52–73CrossRefPubMedGoogle Scholar
  23. 23.
    Boada-Grau J, Merino-Tejedor E, Gil-Ripoll C et al (2014) Adaptación al español del Inventario Multidimensional de Fatiga al entorno laboral. Univ Psychol 13:15–23Google Scholar
  24. 24.
    Bjelland I, Dahl AA, Haug TT, Neckelmann D (2002) The validity of the Hospital Anxiety and Depression Scale: an updated literature review. J Psychosom Res 52:69–77CrossRefPubMedGoogle Scholar
  25. 25.
    Zigmond AS, Snaith RP (1983) The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370CrossRefPubMedGoogle Scholar
  26. 26.
    Ponte C, Sznajd J, O’Neill L, Luqmani R (2014) Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases. Clin Exp Rheumatol 32(sup 85):S118–S125Google Scholar
  27. 27.
    Maruish ME (2011) User’s Manual for the SF-36v2 Health Survey, 3rd edn. QualityMetric Incorporated, LincolnGoogle Scholar
  28. 28.
    Bruce B, Fries JF (2003) The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 30:167–178PubMedGoogle Scholar
  29. 29.
    González V, Stewart A, Ritter P, Lorig K (1995) Translation and validation of arthritis outcome measures into Spanish. Arthritis Rheum 38:1429–1446CrossRefPubMedGoogle Scholar
  30. 30.
    Zúniga MA, Carrillo-Jiménez GT, Fos PJ et al (1999) Evaluación del estado de salud con la Encuesta SF-36: resultados preliminares en México. Salud Publica Mex 41:110–118CrossRefPubMedGoogle Scholar
  31. 31.
    López-Alvarenga JC, Vázquez-Velázquez V, Arcila-Martínez D (2002) Accuracy and diagnostic utility of the Hospital Anxiety and Depression Scale (HAD) in a sample of obese Mexican patients. Rev Invest Clin 54:403–409PubMedGoogle Scholar
  32. 32.
    Escobar-Córdoba F, Eslava-Schmalbach J (2005) Colombian validation of the Pittsburgh Sleep Quality Index. Rev Neurol 40:150–155PubMedGoogle Scholar
  33. 33.
    Durán-Arenas l, Gallegos-Carrillo K, Salinas-Escudero G et al (2004) Hacia una base normativa Mexicana en la medición de calidad de vida relacionada con la salud, mediante el Formato Corto 36. Salud Publica Mex 46:306–315CrossRefPubMedGoogle Scholar
  34. 34.
    Acock AC (2012) A Gentle Introduction to Stata, 3rd edn. Stata Press, TexasGoogle Scholar
  35. 35.
    Basu N, McClean A, Harper L et al (2013) Explaining fatigue in ANCA-associated vasculitis. Rheumatology 52:1680–1685CrossRefPubMedGoogle Scholar
  36. 36.
    Basu N, McClean A, Harper L et al (2014) Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology 53:953–956CrossRefPubMedGoogle Scholar
  37. 37.
    Novakovich E, Grayson PC (2015) What matters for patients with vasculitis? Presse Med 44:e267–e272CrossRefPubMedGoogle Scholar
  38. 38.
    Basu N, Murray AD, Jones GT et al (2014) Neural correlates of fatigue in granulomatosis with polyangiitis: a functional magnetic resonance imaging study. Rheumatology 53:2080–2087CrossRefPubMedGoogle Scholar
  39. 39.
    Carpenter DM, Kadis JA, Devellis RF et al (2011) The effect of medication-related support on the quality of life of patients with vasculitis in relapse and remission. J Rheumatol 38:709–715CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Tomasson G (2013) Quality of life and outcome measures in vasculitis. Best Pract Res Clin Rheumatol 27:69–77CrossRefPubMedGoogle Scholar
  41. 41.
    van Tuyl LH, Boers M (2012) Patient’s global assessment of disease activity: what are we measuring? Arthritis Rheum 64:2811–2813CrossRefPubMedGoogle Scholar
  42. 42.
    Jolly M, Kosinski M, Garris CP, Oglesby AK (2016) Prospective validation of the lupus impact tracker: a patient-completed tool for clinical practice to evaluate the impact of systemic lupus erythematosus. Arthritis Rheumatol 68:1422–1431CrossRefPubMedGoogle Scholar
  43. 43.
    Milman N, Boonen A, Tugwell P, Merkel P (2017) Clinicians’ perspective on key domains in ANCA-associated vasculitis: a Delphi exercise. Scand J Rheumatol 46:112–117CrossRefPubMedGoogle Scholar
  44. 44.
    Robson JC, Milman N, Tomasson G et al (2015) Exploration, development, and validation of patient-reported outcomes in antineutrophil cytoplasmic antibody–associated vasculitis using the OMERACT process. J Rheumatol 42:2204–2209CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Immunology and RheumatologyInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico CityMexico
  2. 2.Department of Neurology and PsychiatryInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico CityMexico

Personalised recommendations